EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pancreatic β‐cell mitogenic regeneration in type 1 diabetes: A preclinical review

James Cantley iD, Lisa Logie iD, Parth Narendran iD, Colin Dayan iD

Diabetic Medicine · 30.10.2026

DOI: 10.1111/dme.70484 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetic Medicine, online erschienen am 30.10.2026. Verfasst von James Cantley und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, Endocrinology and Reproductive Biology, Faculty of Health, Life Sciences Research Complex, University of Dundee, Dundee, UK. Die Arbeit nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Steve Morgan Foundation Type 1 Diabetes Grand Challenge.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 1 diabetes (T1D) is caused by autoimmune destruction of insulin‐producing pancreatic β‐cells, resulting in hyperglycaemia. The first‐line treatment for symptomatic T1D is exogenous insulin replacement to maintain glycaemic control. Islet transplant therapy is available to a small number of individuals, and stem cell‐derived islet transplant therapies are in clinical development. Recent advances in immunotherapy for T1D enable β‐cells to be protected from autoimmune destruction, delaying disease progression. Set against this therapeutic landscape, innate pancreatic β‐cell regeneration strategies have the potential to reverse β‐cell loss in T1D, restoring regulated, endogenous insulin secretion and stable glycaemic control. In this review, we evaluate the preclinical literature investigating β‐cell regeneration strategies via proliferation of residual β‐cells. We cover therapeutic goals for a potential regenerative therapy, drawing on lessons from studies of residual β‐cell function, immunotherapy and islet transplantation in T1D. We review the role of 14 distinct targets/mechanisms with in vitro and/or in vivo data supporting their role in β‐cell proliferation and potential for therapeutic regeneration. In particular, we focus on the role of DYRK1A in β‐cell proliferation, evaluating the range of small molecule inhibitors and in vivo studies underpinning this well‐validated target. We provide perspectives on how future clinical translation could be optimised, including improved drug development, considerations for clinical trial metrics, patient stratification and the potential for combinatorial regenerative and immunotherapy approaches to shield nascent regenerating β‐cells.

Schlagwörter

Stichwörter der Autor:innen

isletpreclinicalregenerationtype 1 diabetespancreatic beta cell

Autor:innen und Institutionen

  • Division of Diabetes, Endocrinology and Reproductive Biology, Faculty of Health, Life Sciences Research Complex, University of Dundee, Dundee, UK.
  • Department of Immunology and Immunotherapy, College of Medicine and Health, University of Birmingham, Birmingham, UK.
  • Department of Diabetes, The Queen Elizabeth Hospital Birmingham, Birmingham, UK.

ORCID-Profile: James Cantley, Lisa Logie, Parth Narendran, Colin Dayan

Förderung

  • Steve Morgan Foundation Type 1 Diabetes Grand Challenge

Zitieren

APA

Cantley, J., Logie, L., Narendran, P., & Dayan, C. (2026). Pancreatic β‐cell mitogenic regeneration in type 1 diabetes: A preclinical review. Diabetic Medicine. https://doi.org/10.1111/dme.70484

Vancouver

Cantley J, Logie L, Narendran P, Dayan C. Pancreatic β‐cell mitogenic regeneration in type 1 diabetes: A preclinical review. Diabetic Medicine. 2026. doi:10.1111/dme.70484

BibTeX
@article{Cantley2026,
  author = {Cantley, James and Logie, Lisa and Narendran, Parth and Dayan, Colin},
  title = {Pancreatic β‐cell mitogenic regeneration in type 1 diabetes: A preclinical review},
  journal = {Diabetic Medicine},
  year = {2026},
  doi = {10.1111/dme.70484}
}
Kostenlos starten →